Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.35 |
| ▸ | CBFB | Q13951 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10139971 | 0.92 | TRPV1 (0.41) | TRPV1P2RY6KCNH2RUNX1CBFB | |
| SCHEMBL7966321 | 0.90 | NPC1 (0.45) | DHODHCYP1A2CYP2C9BRD4KDM4E | |
| SCHEMBL7971674 | 0.87 | PDPK1 (0.42) | CYP1A2CYP3A4CYP2C9CYP2C19KIT | |
| SCHEMBL7971418 | 0.86 | SCD (0.42) | DHODHKITPDE10A | |
| SCHEMBL7962296 | 0.86 | NPBWR1 (0.36) | DHODHMAPK14KDM4ENPC1ALDH1A1 | |
| SCHEMBL7972135 | 0.85 | PDE10A (0.37) | KCNH2PDE10ANPC1POLBRAB9A | |
| SCHEMBL7972259 | 0.84 | FGFR1 (0.40) | KITMAPK14BACE1 | |
| SCHEMBL7971392 | 0.84 | SCD (0.42) | CYP3A4KITBRD4KDM4EALDH1A1 | |
| SCHEMBL7971678 | 0.84 | NPC1 (0.43) | KDM4ENPC1ALDH1A1POLBRAB9A | |
| SCHEMBL7971018 | 0.83 | HSD17B10 (0.37) | P2RY6BRD4PDE10AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805939-B1 | Heterocyclic compounds as factor IXA inhibitors. | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2805939-A1 | Heterocyclic compounds as factor IXA inhibitors. | Merck Sharp & Dohme Corp. (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| WO-2009143039-A2 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | SCHERING CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | F9, F12, F8 | DHODH 538/4885CYP1A2 324/4885CYP3A4 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.